Medicina cardiovascular

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Bioengineered Cardiac Tissue for Hypoplastic Left Heart Syndrome Analysis

   Rochester, Minn.

   The purpose of this study is to produce and characterize patient-specific cardiac tissue for Hypoplastic Left Heart Syndrome (HLHS) using reprogrammed cell technology.

2. A Study to Assess Non-invasive Arterial Air Plethysmography of Normal and Abnormal Arterial Hemodynamics

   Rochester, Minn.

   The purpose of this study is to determine the accuracy (sensitivity, specificity, negative predictive value, positive predictive value) of a non-invasive arterial air plethysmography prototype in people with normal and abnormal arterial hemodynamics.

3. (FMD Impact Registry) Fibromuscular Dysplasia Findings and Outcomes

   Rochester, Minn.

   To describe the clinical, laboratory, pathologic, imaging findings, therapy and outcomes in all patients with Fibromuscular Dysplasia (FMD) and/or segmental arterial mediolysis evaluated at Mayo Clinic retrospectively (back to 01/01/1990) and prospectively (starting 04/13/2016).

4. A Study to Evaluate the Impact of Menopause on Blood Pressure Regulation During Exercise

   Rochester, Minn.

   The purpose of this study is to determine how menopause influences blood pressure responses during exercise in women.

5. A Study of Heart Muscle Elasticity Measured by Echocardiography

   Rochester, Minn.

   The purpose of this study is to evaluate the possibility of using echocardiography to measure heart muscle elasticity in clinical practice.

6. A Study of Lung Ultrasound to Assess Extravascular Lung Water

   Rochester, Minn.

   The purpose of this study is to determine if lung ultrasound surface wave elastography (LUSWE) can accurately detect changes in lung elasticity (compliance) caused by the presence of extravascular lung water  (pulmonary edema).

7. His Bundle Pacing in Bradycardia and Heart Failure

   Rochester, Minn.

   Participants in this study will either have heart failure (HF) and are scheduled to undergo cardiac resynchronization therapy pacemaker (CRT-P) or cardiac resynchronization therapy defibrillator (CRT-D) implantation, or have atrioventricular (AV) block and are scheduled to undergo dual chamber pacemaker implantation. In this study additional heart rhythm measurements will be collected during the implant procedure to better understand how His bundle and/or parahisian pacing (HISP) effects electrical conduction in the hearts of patients with HF or AV block. The hypothesis is that His bundle or parahisian pacing (HISP) may normalize atrioventricular (AV) conduction with a narrow combination of the Q wave, R wave and S wave (QRS complex) in functional bundle branch block or conduction delay in patients with heart failure (HF).

8. Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

   Rochester, Minn.

   The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

9. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

   Rochester, Minn.

   The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

10. the Mayo Cardiac Sarcoid Registry

    Rochester, Minn., Jacksonville, Fla.

    Aims, purpose, or objectives:

    1. Develop a retrospective registry of patients with cardiac sarcoidosis
    2. Develop a prospective registry of patients with cardiac sarcoidosis
    3. Understand the natural history of cardiac sarcoidosis through evaluation of outcomes of patients in the registry
    4. Determine risk factors for sarcoid involvement of the heart
    5. Evaluate outcomes of patients both treated and untreated with cardiac sarcoidosis
    6. Understand the complications of untreated and treated cardiac sarcoidosis